LOS ANGELES, July 17, 2017 (GLOBE NEWSWIRE) — Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) for possible violations of federal securities laws from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Neurotrope shares during the Class Period should contact the firm by the July 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected]
No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information, regarding the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. Upon release of this news, the Company’s stock price dropped materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
CONTACT: Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
Latest posts by Nasdaq NewsFeed (see all)
- Global RX-to-OTC Switching Market Current and Future Trends Report 2017 with Insight from Key Industry Opinion Leaders - November 23, 2017
- CORRECTION of Notice (764/17): Listing of bond loan issued by Fastighets AB Balder (publ) on STO Corporate Bonds (772/17) - November 23, 2017
- Refinancing of RenteMax-loans - November 23, 2017